NBIX

Neurocrine BiosciencesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$208.00

+34.3% vs current

Most likely

Base case

50%

Probability

Target price

$177.00

+14.3% vs current

B-

Bear case

25%

Probability

Target price

$129.00

-16.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Primary-source evidence is constructive but incomplete: the May 5 10-Q and May 28 8-K are real company filings, yet the packet does not include the underlying 8-K item details or a fresh analyst revision wave. Recent media coverage says the stock hit new highs on an earnings surge, which supports a positive tape, but the peer set is not tight enough and forward catalyst visibility is limited, so this remains a tentative monitoring-style view rather than a standard-conviction upgrade.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-05-05eventLatest 10-Q keeps commercial and balance-sheet monitoring in focusMedium impact

The May 5, 2026 10-Q is the most recent primary-source operating update in the packet, so the market is still anchored to the quarter-end financials, cash deployment, and execution cadence rather than a fresh outlook reset. [#10-Q-2026-05-05]

2026-05-28eventMay 28 8-K remains a disclosure watch itemMedium impact

The SEC current report confirms a fresh company filing, but the packet excerpt does not identify the underlying item; this should be monitored as a low-signal disclosure event rather than treated as a thesis-making catalyst. [#8-K-2026-05-28]

2026-09-30catalystPipeline breadth remains the longer-dated upside leverMedium impact

The 10-K/10-Q hints show ongoing non-clinical, preclinical, undisclosed, and gene-therapy programs; the medium-term rerate still depends on clinical, regulatory, and development execution rather than a single near-term binary readout. [#10-K-2026-02-11] [#10-Q-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology